RaySearch Laboratories AB earnings date
Want to see SE:RAY.B full AI Analyst Report?
RaySearch Laboratories AB (RAY.B) Q3 2026 Earnings Report
SE:RAY.B Q3 2026 EPS Results
- Actual EPS
- SEK 1.88
- Consensus EPS
- SEK 2.40
- Beat/Miss
- Missed by -SEK 0.52
- One Year Ago EPS
- SEK 2.09
SE:RAY.B Q3 2026 Revenue Results
- Actual Revenue
- SEK 394.30M
- Expected Revenue
- SEK 379.33M
- Beat/Miss
- Beat by +SEK 14.97M
- YoY Revenue Growth
- +18.66%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/03/2026
- Time
- Before Open
- Conference Call
- Tuesday, November 3, 2026
RaySearch Laboratories AB's next earnings date is estimated for February 10, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was predominantly positive, supported by record Q3 sales, strong order intake, U.S. momentum, strategic customer wins, expanding RayCare adoption, substantial backlog and strong financial flexibility. However, license sales declined, margins were pressured by an unusually high hardware mix, free cash flow was negative, RayCare deal conversion remains gradual, reimbursement-related delays persist, and the full-year EBIT target requires an exceptionally strong fourth quarter.
RaySearch expects growth to continue for the full year of 2026 and also expects a very strong end of 2026, with Q4 traditionally its strongest quarter; management said it will be “a stellar Q4” to achieve the full year EBIT margin target of at least 25%, which “remains within reach,” is “not a given” but “reasonable,” and excludes costs related to the long-term incentive program introduced in the second quarter this year. Management expects a few more RayCare orders this year, said RayCare will contribute in 2027, expects customer receivables to remain at the same high numbers in the next quarter but not increase further, and expects sales and marketing costs to be on about the same level in the next quarter as in this.
- Broad Platform Reach and Patient ImpactRaySearch has four software platforms—RayStation, RayCare, RayIntelligence and RayCommand—480 employees across 31 nationalities, 26 industrial partners, and 1,248 clinics in 54 countries using RayStation. The company's software has been used to treat over 11 million cancer patients.
- Record Quarterly Sales and Strong Organic GrowthQ3 sales reached a record-high SEK 394 million, representing 19% growth and 18% organic growth. Recurring support revenue accounted for 35% of total revenue, and the EBIT margin was 21%.
- Strong Demand Across Proton and Photon TherapyRaySearch continued to see strong demand across both proton and photon therapy, particularly in the U.S.
- Expanded Accuray Collaboration and Significant OrderThe collaboration with Accuray was expanded in online adaptive therapy, including a significant RayStation order worth $8 million. SEK 33 million was recognized as revenue in Q3, with the remaining revenue expected in Q4.
- U.S. Proton Therapy WinsRaySearch received several U.S. proton therapy orders. The University of North Carolina School of Medicine expanded its RayStation installation with additional licenses, while Sylvester Comprehensive Cancer Center selected RayStation to replace ECLIPSE for its Varian ProBeam system.
- Photon Therapy ConversionsPhoton therapy demand remained strong, with several clinics replacing ECLIPSE, Monaco, Pinnacle and Precision with RayStation. Management said ECLIPSE and Monaco conversions had increased year-to-date, supported by interest in online adaptive therapy and a gradual shift in sales focus toward competing systems beyond Pinnacle.
- RayCare and RayStation Milestone at ARTAdvanced Radiation Therapeutics in the U.S. began treating patients using RayCare and RayStation together with the Varian TrueBeam, creating another important RayCare reference clinic and supporting broader adoption of RayCare in the U.S.
- Strong Interest in Product InnovationsAt the ASTRO conference in Boston, RaySearch showcased innovations in automation, speed and advanced analytics and reported strong interest in its solutions.
- Share Buybacks and Shareholder ReturnsRaySearch carried out additional share buybacks of SEK 58 million during the quarter, reducing the number of outstanding shares. During 2026, the company returned SEK 337 million to shareholders through share buybacks and dividends.
- New Multi-Year IAEA PartnershipRaySearch entered a multi-year partnership with the International Atomic Energy Agency as part of the Rays of Hope initiative. The company will provide software training and technical expertise to IAEA anchor and regional centers supporting radiotherapy capabilities in low- and middle-income countries.
- Accelerating Order Intake and BacklogLicense orders increased 65% and total order intake increased 30% in Q3. The book-to-bill ratio was 1, and the order backlog at the end of September was SEK 1.722 million, of which SEK 665 million was expected to turn into net sales in the next 12 months. Management said order intake was trending upward toward a higher level.
- U.S. Orders Back on TrackThe Americas returned to stronger order intake, supported by the Accuray order and several additional U.S. photon conversions from Varian and Elekta.
- Support Revenue GrowthSupport revenue grew 6% in Q3, or 7% when adjusted for currency. Recurring support revenue represented 40% of sales over the last 12 months.
- Strong Financial FlexibilityDespite returning SEK 337 million to shareholders during 2026, RaySearch ended Q3 with a net cash position of SEK 92 million, excluding office and car lease liabilities, and had SEK 234 million in undrawn credit facilities.
- Positive U.S. Momentum and Growth PipelineManagement said the U.S. continued to show good momentum in both sales and productivity and remained an important growth driver. The company cited a robust pipeline in the growing proton market, increasing market share in the larger photon market, and additional opportunities among existing customers through modules and solutions.
- Expansion Beyond Radiation TherapyOver the longer term, RaySearch is gradually broadening its offering beyond radiation therapy, with an ambition to provide integrated software support for other cancer treatment methods such as surgery and chemotherapy.
- Confidence in a Strong Year-EndManagement expects a very strong end to 2026 and said the full-year EBIT margin target of at least 25% remains within reach, excluding costs related to the long-term incentive program introduced in Q2.
- RayCare Integration and Future ContributionMachine integration work for RayCare is ongoing across many fronts, with a large number of machines being connected. Management expects a few more RayCare orders during 2026 and believes RayCare will contribute to growth in 2027.
- Stable Proton License SalesProton license sales during the first nine months of 2026 were described as being at a similar level to the corresponding period of the prior year.
SE:RAY.B Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 10, 2027 | 2026 (Q4) | 2.81- | 2 | ― | ― |
| Nov 03, 2026 | 2026 (Q3) | 2.401.88 | 2.09 | -10.29% (-0.21) | |
| Aug 13, 2026 | 2026 (Q2) | ―0.57 | 0.9 | -36.67% (-0.33) | |
| Jul 16, 2026 | 2027 (Q2) | 1.190.57 | 0.9 | -36.67% (-0.33) | |
| Apr 29, 2026 | 2026 (Q1) | 1.481.55 | 1.66 | -6.33% (-0.10) | |
| Feb 12, 2026 | 2025 (Q4) | 1.562.00 | 1.75 | 14.29% (+0.25) | |
| Nov 07, 2025 | 2025 (Q3) | 1.322.09 | 1.32 | 58.33% (+0.77) | |
| Aug 08, 2025 | 2025 (Q2) | 1.110.90 | 1.79 | -49.72% (-0.89) | |
| May 09, 2025 | 2025 (Q1) | 1.151.66 | 1.07 | 55.14% (+0.59) | |
| Feb 21, 2025 | 2024 (Q4) | 1.321.75 | 0.92 | 90.22% (+0.83) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.


